Physician profile
Lisa C Espinoza
NPI 1053534628
$722,341.33
in general payments reported to CMS, 2019-2025
8 companies · $154K in 2025
The $154K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $71K · 2021: $107K · 2022: $105K · 2023: $109K · 2024: $133K · 2025: $154K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $197K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $45K · Food and Beverage: $6,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $197,143.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,159.49 |
| Travel and Lodging | $45,190.14 |
| Food and Beverage | $6,694.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316,095.24 | 2023-2025 | |
| Galderma Laboratories, L.P. | $205,465.72 | 2019-2025 | Dysport |
| Allergan, INC. | $200,608.63 | 2019-2023 | |
| Pfizer INC. | $107.24 | 2019 | |
| Merz North America, INC. | $18.87 | 2023 | |
| Musculoskeletal Transplant Foundation INC. | $18.65 | 2024 | |
| Revance Therapeutics, INC. | $15.00 | 2025 | Daxxify |
| Novo Nordisk INC | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.